TGA Sciences, Inc (“TGA”) and Sanguine BioSciences, Inc (“Sanguine”) have entered into a co-marketing agreement, in which Sanguine will market TGA’s Bioassay Development services in conjunction with its rapidly-expanding product offering, including PBMC and biospecimen from healthy and patient donors. As Sanguine increases its presence on the biomarker development front, the company’s clients will demand bioassay development services, and TGA is now well positioned to receive a larger volume of requests for biomarker development services.
“It comes to no surprise that Sanguine’s clientele demand biomarker assay work in conjunction to the biospecimen they purchase. This relationship with TGA will enable us to provide them with additional services from a renowned CRO with rich experience in cell-based bioassays,” stated David Winternheimer, PhD, Vice President of Biospecimen Marketing for Sanguine. Michael Settles, President of TGA Sciences said “We are excited to enter into this co-marketing agreement with Sanguine, and are hopeful it will help us expand our client base in Europe as well as help us increase the scope of our bioassay services.”
About TGA Sciences, Inc.: TGA Sciences, Inc. is a Medford, MA based contract research organization that specializes in bioanalytical and immunological services conducted under GLP, and in vivo animal services conducted under cGMP guidelines. The company prides itself on its ability to be flexible to its customers assay development and validation needs. The 24,000 ft² facility encompasses 5 individual labs and is ideal for virtual and large biotech, pharmaceutical and medical device companies. TGA is FDA / EMA inspected, DEA accredited, OLAW licensed and AAALAC accredited. Further information can be found at www.tgasciences.com
About Sanguine BioSciences: Sanguine BioSciences, a biorepository, based in Santa Monica, California provides high quality human biospecimen and primary cells to the academic and industrial life science research community for the purposes of Basic Research and Drug & Biomarker Development. The product offering spans customers’ needs mainly in the In Vitro Research & Development stage of Drug Development. Sanguine’s vision is to develop into the global leader in high quality cells and tissues for life science research and development. Further information can be found at www.sanguinebio.com